Industry News

Search Articles:

FDA approves two new indications for Merck’s KEYTRUDA® (pembrolizumab)
Merck announced the FDA has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy in patients whose tumors express PD-L1 (Combined Positive Score [≥1) or in combination with platinum and fluorouracil or first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.June 11, 2019